Search

Your search keyword '"Cordie, Ahmed"' showing total 128 results
Start Over Author "Cordie, Ahmed"
128 results on '"Cordie, Ahmed"'

5. FRI-273-YI Prevalence, characteristics and hepatic fibrosis burden of the different subtypes of steatotic liver disease among a cohort of Egyptian people living with HIV

Author

Mohamed, Rahma, primary, Omar, Heba, additional, El Garhy, Naeema, additional, Cordie, Ahmed, additional, Tamim, Hend, additional, Masoud, Zainab, additional, Sehemy, Lamiaa Al, additional, Hatem, Ammar, additional, Awad, Reham Awad, additional, Abdelraouf, Mariam Ismail, additional, Al-sharif, Aya M., additional, Sherif, Mirella, additional, Saweres, Andrew, additional, Atef, Remon, additional, Nagy, Mohamed, additional, Hamza, Rania, additional, Hamdy, Mona Salah Eldin, additional, Khateeb, Engy El, additional, and Esmat, Gamal, additional

Published
2024
Full Text
View/download PDF

7. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study

Author

Biccard, Bruce M, Gopalan, Pragasan Dean, Miller, Malcolm, Michell, William Lance, Thomson, David, Ademuyiwa, Adesoji, Aniteye, Ernest, Calligaro, Greg, Chaibou, Maman Sani, Dhufera, Hailu Tamiru, Elfagieh, Mohamed, Elfiky, Mahmoud, Elhadi, Muhammed, Fawzy, Maher, Fredericks, David, Gebre, Meseret, Bayih, Abebe Genetu, Hardy, Anneli, Joubert, Ivan, Kifle, Fitsum, Kluyts, Hyla-Louise, Macleod, Kieran, Mekonnen, Zelalem, Mer, Mervyn, Morais, Atilio, Msosa, Vanessa, Mulwafu, Wakisa, Ndonga, Andrew, Ngumi, Zipporah, Omigbodun, Akinyinka, Owoo, Christian, Paruk, Fathima, Piercy, Jenna Louise, Seman, Yakob, Taylor, Elliott H, van Straaten, Dawid, Awad, Ahmed, Hussein, Hend, Shaban, Mahmoud, Elbadawy, Merihan, Elmehrath, Ahmed O, Cordie, Ahmed, Elganainy, Mohamed, El-Shazly, Mostafa, Essam, Mahmoud, Abdelwahab, Omar A., Ali, Aboubakr, Hussein, Aliae Mohamed, kamel, Emad Zarief, Monib, Fatma A., Ahmed, Islam, Saad, Mahmoud M., Al-Quossi, Mohammed Ali, Rafaat, Nashwa, Galal, Islam, labib, Beshoui, Omran, Dalia Omran, Azzam, Ahmed, Azab, Mohammed, Ghozy, Sherief, Tawheed, Ahmed, Gamal, Mahmoud, El Kassas, Mohamed, Azzam, Aml, Ahmed, Neama, NasrEldin, Yasmin, Abdelsalam, Ali, Abdewahab, Omar, Elmandouh, Omar, Addisie, Abebe, Eshete, Akine, Desita, Kokeb, Araya, Hiruy, Agidew, Yared, Andabo, Addisu Desalegn, Tesfaye, Emnet, Yesuf, Elias Ali, Hailemariam, Gelaw, Sime, Habtamu, Keneni, Dame Fikadu, Mohammed, Menbeu Sultan, Gebremedhin, Yemane, Taye, Yoseph, Mebrate, Tamiru Assefa, Gemechu, Tirunesh Busha, Bedane, Tigist Tesfaye, Abera, Elias Tewabe, Teshome, Ayele, Doku, Alfred, Afriyie-Mensah, Jane Sandra, Lawson, Aba, Sottie, Daniel Akwanfo, Addae, Emma, Ofosu-Appiah, Ernest, Obeng, William, Mugera, Anne, Bitta, Caesar, Huwaysh, Mohammed Abdalraheem, Yahya, Mohammed Mahdi Ali, Mohammed, Alsnosy Abdullah Khalefa, Majeed, Amrajaa Alsalihin Mohammed, Mohammed, Amkhatirah Emad Mousay, Majeed, Elsalhein, Abusalama, Abdurraouf A, Altayr, Ehab, Abubaker, Taha, Alkaseek, Akram Mohammed, Abdulhafith, Butaina, Alziyituni, Zainab, Gamra, Marwa F, Anaiba, Mohamed Muftah, Khel, Samer, Abdelkabir, Mohammed, Abdeewi, Saedah, Adam, Safia, Alhadi, Abdulmueti, Alsoufi, Ahmed, Binnawara, Muhannad, Msherghi, Ahmed, Bouhuwaish, Ahmad Elmabri Mohammad, Taher, Ahmed SA, Masoo, Francis, Chikumbanje, Singatiya Stella, Chisala, Palesa, Mabedi, Delia, Carlos, Antonio, Lorenzoni, Cesaltina, Mambo, Jorge, Isabel Chissaque, Isabel, Mouzinho Saide, Mouzinho, Mamane, Maikassoua, Amadou, Foumakoye, Adesoji Ademuyiwa, Adesoji Ademuyiwa, Akinyinka Omigbodun, Akinyinka Omigbodun, Adeyeye, Ademola, Akinmade, Akinola, Momohsani, Yakubu, Bamigboye, John, Orshio, Donald, Isamade, Erdoo Suckie, Embu, Henry, Nuhu, Samuel, Ojiakor, Samuel, Nuhu, Ahmed, Kwayabura, Salisu, Fowotade, Adeola, Sanusi, Arinola, Osinaike, Babatunde, Idowu, Olusola, Adekanmbi, Olukemi, Amali, Abdullahi Oteikwu, Ibrahim, Sanusi, Adamu, Adamu Abba, Kida, Ibrahim, Otokwala, Job, Alagbe-Briggs, Olubusola, Ojum, Sylvanus, Scribante, Juan, Kalla, Ismail Sikander, Mdladla, Aurence, Mabotja, Tebogo, Naidoo, Ria, Matos-Puig, Roel, Ramkillawan, Arisha, Smith, Michelle, Arnold-Day, Christel, Jagga, Jagga, Piercy, Jenna, Michell, Lance, Devenish, Liam, Fernandes, Nicole, Pershad, Santosh, Grabowski, Nicola, Rammego, Mapule, Zwane, Sabelo, Dhlamini, Masikhanyise Elizabeth, Neuhoff, Matthew, Fodo, Tobisa, Usenbo, Anthony, Mrara, Busisiwe, Kabambi, Freddy, Cloete, Estie, De Caires, Leonel, Dickerson, Roger, Louw, Candice, Theron, Alida, Herselman, Ryan, Badenhorst, Jannes, Moletsane, Godfrey, Loots, Helene, Vorster, Frans Christiaan, Chausse, Julian, Sebastian, Melinda, Rheeder, Paul, van Hougenhouck-Tulleken, Wesley, Snyman, Carin, Adeleke, Durotolu, Esterhuizen, Jovan, de Man, Leoni, Mosola, Matema, van der Linde, Pieter, Swart, Reinier, Maasdorp, Shaun, Martins, Tina, and Govender, Veneshree

Published
2021
Full Text
View/download PDF

10. Pattern of transient elastography in Egyptian people living with HIV: predictors of hepatic steatosis and fibrosis

Author

El Garhy, Naeema, primary, Al sehemy, Lamiaa, additional, Awad Ibrahem, Reham Awad, additional, Abdelraouf, Mariam I., additional, Hatem, Ammar, additional, Al-shari, Aya M., additional, Karam-Allah, Haidi, additional, Alkhatib, Engy, additional, Mohamed, Rahma, additional, Esmat, Gamal, additional, and Cordie, Ahmed, additional

Published
2023
Full Text
View/download PDF

12. A multinational Delphi consensus to end the COVID-19 public health threat

Author

Lazarus, Jeffrey V., Romero, Diana, Kopka, Christopher J., Karim, Salim Abdool, Abu-Raddad, Laith J., Almeida, Gisele, Baptista-Leite, Ricardo, Barocas, Joshua A., Barreto, Mauricio L., Bar-Yam, Yaneer, Bassat, Quique, Batista, Carolina, Bazilian, Morgan, Chiou, Shu-Ti, del Rio, Carlos, Dore, Gregory J., Gao, George F., Gostin, Lawrence O., Hellard, Margaret, Jimenez, Jose L., Kang, Gagandeep, Lee, Nancy, Matičič, Mojca, McKee, Martin, Nsanzimana, Sabin, Oliu-Barton, Miquel, Pradelski, Bary, Pyzik, Oksana, Rabin, Kenneth, Raina, Sunil, Rashid, Sabina Faiz, Rathe, Magdalena, Saenz, Rocio, Singh, Sudhvir, Trock-Hempler, Malene, Villapol, Sonia, Yap, Peiling, Binagwaho, Agnes, Kamarulzaman, Adeeba, El-Mohandes, Ayman, Barreto, Mauricio, Abdulla, Salim, Addleman, Sarah, Aghayeva, Gulnara, Agius, Raymond, Ahmed, Mohammed, Ramy, Mohamed Ahmed, Aide, Pedro, Aleman, Soo, Alfred, Jean-Patrick, Ali, Shamim, Aliaga, Jorge, Aloudat, Tammam, Alqahtani, Saleh A., Al-Salman, Jameela, Amuasi, John H., Agrawal, Anurag, Anwar, Wagida, Araujo-Jorge, Tania, Artaza, Osvaldo, Asadi, Leyla, Awuku, Yaw, Baker, Michael, Barberia, Lorena, Bascolo, Ernesto, Belcher, Paul, Bell, Lizett, Benzaken, Adele, Bergholtz, Emil, Bhadelia, Nahid, Bhan, Anant, Bilodeau, Stephane, Bitrán, Ricardo, Bluyssen, Philomena, Bosman, Arnold, Bozza, Fernando A., Brinkmann, Melanie M., Brown, Andrew, Mellado, Bruce, Bukusi, Elizabeth, Bullen, Chris, Buonanno, Giorgio, Burgess, Rochelle, Butler, Matthew, Byakika-Kibwika, Pauline, Cabieses, Baltica, Carlsson, Gunilla, Cascini, Fidelia, Chabala, Chishala, Chakroun, Mohamed, Cheng, null, Chetty, Agnes, Chumachenko, Dmytro, Consalves, Gregg, Conway Morris, Andrew, Cordie, Ahmed, Corrah, Tumani, Crabtree-Ramírez, Brenda, Dashdorj, Naranjargal, Davidovitch, Nadav, de Souza, Luis Eugenio, Dhariwal, Akshay Chand, Druică, Elena, Ergonul, Onder, Erondu, Ngozi A., Essar, Mohammad Yasir, Ewing, Andrew, Fanjul, Gonzalo, Feierstein, Daniel, Feigl-Ding, Eric, Figueroa, Ramon, Figueroa, John Peter, Fisher, Dale, Flores, Walter, Forero-Peña, David A., Frumkin, Howard, Gamkrelidze, Amiran, Gandhi, Monica, Garcia, Patricia, Garcia-Basteiro, Alberto L., García-Sastre, Adolfo, Garg, Suneela, Gbeasor-Komlanvi, null, Gershenson, Carlos, Gilada, Ishwar, Giovanella, Ligia, González, Marino, Green, Manfred S., Greenhalgh, Trisha, Griffin, Paul, Griffin, Stephen, Grinsztejn, Beatriz, Anand, Tanu, Guerra, Germán, Guinto, Renzo, Gujski, Mariusz, Guner, Rahmet, Hamdy, Adam, Hâncean, Marian-Gabriel, Haniffa, Abusayeed, Hartigan-Go, Kenneth Y., Hassan, Hoda K., Hay, Simon I., Heino, Matti T. J., Hel, Zdenek, Hotez, Peter, Hu, Jia, Hukić, Mirsada, IJsselmuiden, Carel, Iroko, Davidson, Iskarous, Maged, Izugbara, Chimaraoke, Jacobs, Choolwe, Jadad, Alejandro R., Jehan, Fyezah, Jordan, Ayana, Jroundi, Imane, Kain, Kevin, Kamberi, Fatjona, Karamov, Eduard, Karan, Abraar, Katz, Rebecca, Katzourakis, Aris, Kazembe, Abigail, Khamis, Faryal, Khamzayev, Komiljon, Khanyola, Judy, Khunti, Kamlesh, Kiguli-Malwadde, Elsie, Kim, Woo Joo, Kirenga, Bruce J., Klimovský, Daniel, Kmush, Brittany L., Knaul, Felicia, Kogevinas, Manolis, Kristensen, Frederik, Kumar, Dinesh, Kumar, Raman, Kvalsvig, Amanda, Lacerda, Marcus V., Lal, Arush, Lawton, Tom, Lemery, Jay, Leonardi, Anthony J., Li, Yuguo, Löttvall, Jan, Lounis, Mohamed, Maceira, Daniel, MacIntyre, C. Raina, Madani, Azzeddine, Magiorkinis, Gkikas, Malekzadeh, Reza, Choisy, Marc, Marcelin, Jasmine R., Marks, Guy B., Marr, Linsey, Marrazzo, Jeanne, Martina, Antonieta, Martín-Moreno, José M., Mateos, Carlos, Mayxay, Mayfong, Mazarati, Jean Bapiste, Mboup, Souleymane, McDonald, Jennifer, McMillan, Faye, Mechili, Enkeleint, Medici, Andre, Davis, Sarah L. M., Meier, Petra, Memish, Ziad A., Menon, Jaideep, Menon, Purnima, Mesiano-Crookston, Jonathan, Michie, Susan, Mikolasevic, Ivana, Milicevic, Ognjen, Mishra, Asit Kumar, Mohamed, Rahma, Mokdad, Ali H., Monroy-Valle, Michele, Morawska, Lidia, Moschos, Sterghios A., Motawea, Karam, Mousavi, Sayed Hamid, Mumtaz, Ghina, Munene, Peter K., Muñoz Almagro, Carmen, Muriuki, Janet, Muyingo, Sylvia, Naniche, Denise, Naylor, C. David, Ndembi, Nicaise, Nemec, Juraj, Nesteruk, Igor, Ngaruiya, Christine, Nguyen, Hung, Nikolova, Dafina, Nitzan, Dorit, Norheim, Ole, Noushad, Mohammed, Ntoumi, Francine, Nyborg, Gunhild Alvik, Ochodo, Eleanor, Odabasi, Zekaver, Okwen, Mbah Patrick, Olivia, Keiser, Ong, David S. Y., Opara, Ijeoma, Orozco, Miguel, Oshitani, Hitoshi, Pagel, Christina, Pai, Madhukar, Pálsdóttir, Björg, Papatheodoridis, Georgios, Paraskevis, Dimitrios, Leigh, Jeanna Parsons, Pécoul, Bernard, Peichl, Andreas, Perez-Then, Eddy, Duc, Phuc Pham, Philippe, Cécile, Pineda Rojas, Andrea, Pladsen, Courtney, Pozniak, Anton, Quiroga, Rodrigo, Qureshi, Huma, Rampal, Sanjay, Ranney, Megan, Rathe, Laura, Ratzan, Scott, Raventos, Henriette, Rees, Helen, Reis, Renata, Ricciardi, Walter, Rizk, Nesrine, Robalo, Magda, Robertson, Eleanor, Robinson, Leanne, Rokx, Casper, Ros, Tamsin, Røttingen, John-Arne, Rubin, Meir, Ruxrungtam, Kiat, Sadirova, Shakhlo, Saha, Senjuti, Salgado, Nelly, Sanchez, Lizet, Sangaramoorthy, Thurka, Santamaria-Ulloa, Carolina, Santos, Renata, Sawaf, Bisher, Schneider, Matthias F., Schooley, Robert T., Sener, Alper, Sepulveda, Jaime, Shah, Jaffer, Shibani, Mosa, Shoib, Sheikh, Sikazwe, Izukanji, Šimaitis, Aistis, Gill, Amandeep Singh, Skhvitaridze, Natia, Sokolović, Milka, Solomon, Roma, Solórzano, Xavier, Springer, Sandra A., Šrol, Jakub, Staines, Anthony, Stelfox, Henry T., Strathdee, Steffanie, Sulaiman, Lokman Hakim, Sutton, Brett, Svanæs, Dag, Swed, Sarya, Sypsa, Vana, Sørensen, Kristine, Tajudeen, Raji, Tan, Amy, Tang, Julian, Tanner, Marcel, Sethi, Tavpritesh, Temmerman, Marleen, Than, Kyu Kyu, Tinto, Halidou, Tomètissi, Sênoudé Pacôme, Torres, Irene, Tshering, null, Tsiodras, Sotirios, Tsofa, Benjamin, Vahlne, Anders, Vargas, Juan Rafael, Bernal, Ivan Dario Velez, Ventura, Deisy, Vilasanjuan, Rafael, Vipond, Joe, Wamala-Andersson, Sarah, Wargocki, Pawel, West, Robert, Weyand, Angela, White, Trenton M., Wolff, Guntram, Yao, Maosheng, Yates, Christian A., Yeboah, Georgina, Yee-Sin, Leo, Yi, Siyan, Teo, Yik-Ying, Yong, Poovorawan, Zamora-Mesía, Victor, Øvrehus, Anne, 0000-0001-9618-2299, 0000-0002-4832-9564, 0000-0002-4986-2133, 0000-0003-0790-0506, 0000-0003-0875-7596, 0000-0002-6994-1891, 0000-0002-3869-615X, 0000-0001-5286-4044, 0000-0001-6203-1847, 0000-0002-0121-9683, 0000-0003-1793-6350, 0000-0003-2418-0037, 0000-0002-5095-748X, 0000-0003-4492-3256, 0000-0002-5964-8210, 0000-0002-6779-3151, 0000-0002-8074-4450, Lazarus, Jeffrey V [0000-0001-9618-2299], Romero, Diana [0000-0002-4832-9564], Karim, Salim Abdool [0000-0002-4986-2133], Abu-Raddad, Laith J [0000-0003-0790-0506], Bassat, Quique [0000-0003-0875-7596], Chiou, Shu-Ti [0000-0002-6994-1891], Gao, George F [0000-0002-3869-615X], Gostin, Lawrence O [0000-0001-5286-4044], Jimenez, Jose L [0000-0001-6203-1847], McKee, Martin [0000-0002-0121-9683], Oliu-Barton, Miquel [0000-0003-1793-6350], Pradelski, Bary [0000-0003-2418-0037], Rathe, Magdalena [0000-0002-5095-748X], Trock-Hempler, Malene [0000-0003-4492-3256], Yap, Peiling [0000-0002-5964-8210], Binagwaho, Agnes [0000-0002-6779-3151], Kamarulzaman, Adeeba [0000-0002-8074-4450], Apollo - University of Cambridge Repository, Helsinki Collegium for Advanced Studies, Research Group of Nelli Hankonen, Doctoral Programme in Social Sciences, Academic Disciplines of the Faculty of Social Sciences, RS: CAPHRI - R2 - Creating Value-Based Health Care, International Health, Performance analysis and optimization of LARge Infrastructures and Systems (POLARIS), Inria Grenoble - Rhône-Alpes, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire d'Informatique de Grenoble (LIG), Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS), Internal Medicine, Medical Microbiology & Infectious Diseases, Veritati - Repositório Institucional da Universidade Católica Portuguesa, and Lazarus J. V., Romero D., Kopka C. J., Karim S. A., Abu-Raddad L. J., Almeida G., Baptista-Leite R., Barocas J. A., Barreto M. L., Bar-Yam Y., et al.

Subjects
Pandemics/economics, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences, COVID-19 Vaccines, Delphi Technique, General Science & Technology, International Cooperation, Temel Bilimler (SCI), ÇOK DİSİPLİNLİ BİLİMLER, Public Health/economics, [SHS]Humanities and Social Sciences, SDG 3 - Good Health and Well-being, RA0421 Public health. Hygiene. Preventive Medicine, Medicine and Health Sciences, Humans, prevention and control, human, Settore MED/42 - IGIENE GENERALE E APPLICATA, Health Education, Pandemics, Multidisipliner, Organizations, Multidisciplinary, MULTIDISCIPLINARY SCIENCES, COVID-19/economics, Temel Bilimler, pandemic, Communication, Health Policy, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti, Doğa Bilimleri Genel, COVID-19, 3142 Public health care science, environmental and occupational health, Delphi study, NATURAL SCIENCES, GENERAL, N/A, Public Opinion, Government, Natural Sciences (SCI), Public Health, Natural Sciences
Abstract

Despite notable scientific and medical advances, broader political, socioeconomic and behavioural factors continue to undercut the response to the COVID-19 pandemic . Here we convened, as part of this Delphi study, a diverse, multidisciplinary panel of 386 academic, health, non-governmental organization, government and other experts in COVID-19 response from 112 countries and territories to recommend specific actions to end this persistent global threat to public health. The panel developed a set of 41 consensus statements and 57 recommendations to governments, health systems, industry and other key stakeholders across six domains: communication; health systems; vaccination; prevention; treatment and care; and inequities. In the wake of nearly three years of fragmented global and national responses, it is instructive to note that three of the highest-ranked recommendations call for the adoption of whole-of-society and whole-of-government approaches , while maintaining proven prevention measures using a vaccines-plus approach that employs a range of public health and financial support measures to complement vaccination. Other recommendations with at least 99% combined agreement advise governments and other stakeholders to improve communication, rebuild public trust and engage communities in the management of pandemic responses. The findings of the study, which have been further endorsed by 184 organizations globally, include points of unanimous agreement, as well as six recommendations with >5% disagreement, that provide health and social policy actions to address inadequacies in the pandemic response and help to bring this public health threat to an end.

Published
2022
Full Text
View/download PDF

18. COVID-19 vaccine acceptance and associated factors among people living with HIV in the Middle East and North Africa region

Author

Mohamed, Rahma, primary, White, Trenton M., additional, Lazarus, Jeffrey V., additional, Salem, Amany, additional, Kaki, Reham, additional, Marrakchi, Wafa, additional, M Kheir, Sara G., additional, Amer, Ibrahim, additional, M Ahmed, Fida, additional, A Khayat, Maie, additional, Al-Abdullah, Nabeela, additional, Ali, Batool, additional, Sultan, Roaa, additional, Alamri, Bandar, additional, Abdulmajid, Anouf, additional, Kooli, Ikbal, additional, Chakroun, Mohamed, additional, Madani, Tariq A., additional, Esmat, Gamal, additional, and Cordie, Ahmed, additional

Published
2022
Full Text
View/download PDF

20. Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies.

Author

Alem, Shereen Abdel, Garhy, Naeema El, Khateeb, Engy El, Khalil, Mahmoud, Cordie, Ahmed, Elsharkawy, Aisha, Fouad, Rabab, Esmat, Gamal, and Abdelbary, Mohammad Salah

Subjects
HEPATITIS C virus, MIXED infections, GLOMERULAR filtration rate, CHRONIC kidney failure, SOFOSBUVIR
Abstract

Background Sofosbuvir (SOF) is authorized for hepatitis C virus (HCV) patients. The nephrotoxicity of SOF on HCV mono-infected and HCV–human immunodeficiency virus (HIV) individuals receiving antiretroviral therapy (ART) remains controversial. Methods A prospective study including 159 HCV mono-infected and 124 HCV–HIV individuals (47 were ART naïve and 77 were tenofovir [TDF]-based ART) who presented with an estimated glomerular filtration rate (eGFR) ≥30 ml/min/1.73 m2 at baseline and were treated with SOF–daclatasvir for 12 weeks. The eGFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration equation over the study period. Results HCV patients had a progressive decline in median levels of eGFR compared with HCV–HIV patients who were ART naïve and those receiving TDF-based ART during and after discontinuing SOF–DAC treatment (96, 109 and 114 at baseline vs 94, 117 and 108 at the end of treatment [EOT]) vs 95, 114 and 115 ml/min/1.73 m2 at 12 weeks after treatment [SVR12], respectively). Moreover, the rate of eGFR stage worsening was more pronounced in HCV mono-infected compared with HCV–HIV individuals who were ART naïve and those receiving TDF-based ART (21.4% vs 8.5% and 14.3% at EOT; 21.4% vs 2.1% and 6.5% at SVR12, respectively). Multivariable regression analysis showed that baseline variables were not independent predictors of eGFR stage worsening either at EOT or SVR12. Conclusions Because the changes in eGFR were minimal and not of clinical significance, and TDF was not associated with an increase in renal dysfunction, SOF-based direct-acting antivirals could be safely used in HCV mono-infected and HCV–HIV individuals, even in those on TDF-based ART. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. HIV-related stigma and discrimination by healthcare workers in Egypt

Author

Galal, Yasmine Samir, primary, Khairy, Walaa Ahmed, additional, Mohamed, Rahma, additional, Esmat, Gamal, additional, Negm, Mohamed, additional, Alaty, Waleed Hamed Abd, additional, Saeed, Maysaa A, additional, Fouad, Rabab, additional, Elzahaby, Amgad Ali, additional, Zaky, Samy, additional, Sakr, Mohamed A, additional, and Cordie, Ahmed, additional

Published
2022
Full Text
View/download PDF

24. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience

Author

Abdelaziz, Hossam, primary, Omar, Heba, additional, Khalil, Mahmoud, additional, Cordie, Ahmed, additional, Mohamed, Rahma, additional, AbdAllah, Mohamed, additional, Abdel Maksoud, Mohammed Hamdy, additional, El Garhy, Naeema, additional, Ali, Lamiaa, additional, El Serafy, Magdy, additional, Esmat, Gamal, additional, and Doss, Wahid, additional

Published
2021
Full Text
View/download PDF

26. The evolving challenges confronting adults living with HIV in three North African countries during the COVID-19 crisis: a survey-based study

Author

Cordie, Ahmed, primary, AbdAllah, Mohamed, additional, El Desouky, Eman, additional, Kheir, Sara Gabrallah Mohamed, additional, Kooli, Ikbal, additional, Awad Mousnad, Mohamed, additional, Idris, Fatima Haj, additional, Abdella, Heba, additional, Chakroun, Mohamed, additional, and Esmat, Gamal, additional

Published
2021
Full Text
View/download PDF

27. Age and frailty are independently associated with increased covid-19 mortality and increased care needs in survivors: results of an international multi-centre study

Author

Alsahab, Mustafa, Beishon, Lucy, Brown, Bryony, Burn, Elinor, Burton, Jenni K, Cox, Natalie, Dani, Melanie, Elhadi, Muhammed, Freshwater, Sarah, Gaunt, Victoria, Gordon, Adam, Goujon, Marie, Hale, Matthew, Hughes, Terry, Jackson, Thomas A, Jelley, Benjamin, Khan, Asma, Khiroya, Heena, Lal, Rajni, Madden, Katy, Magill, Laura, Masoli, Jane, Masud, Tahir, McCluskey, Lauren, McNeela, Natalie, Mohammedseid-Nurhussien, Awolkhier, Moorey, Hannah, Lochlainn, Mary Ni, Nirantharakumar, Krishnarajah, Okoth, Kelvin, Osuafor, Christopher N, Patterson, Katherine, Pearson, Grace M E, Perry, Rita, Pettitt, Michala, Pigott, Jennifer, Pinkney, Thomas, Quinn, Terence, Reynolds, Abigail, Richardson, Sarah, Sanyal, Nik, Seed, Adam, Sleeman, Isobel, Soo, Chee, Steves, Claire, Strain, W David, Taylor, Joanne, Torsney, Kelli, Welch, Carly, Wilson, Daisy, Witham, Miles, Elazeem, Hossam Aldein S Abd, Abdelhafez, Mohammed H, Abdelmalak, Amir, Abdelwahab, Omar A, Abdulhadi, Osama M A S, Adewole, Olubayode, Ahmad, Mohammed, Ahmed, Eltayeb A, Ahmed, Hazem, Ahmed, Islam A, Akcay, Mertcan, Akdeniz, Yeşim, Akın, Emrah, Akladious, Carolyn, Alessandri, Francesco, Ali, Ali, Aljafari, Abdulmalek, Aljafari, Abdulmoiz, Al-Sadawi, Mohammed, Al-Sodani, Lobna, Altintoprak, Fatih, Amaratungaz, Gitanjali, Amer, Jocelyn, Amini, Sylvia, Amir, Taha, Anandarajah, Cheran, Anders, Rachael, Ansari, Muhammed H, Appiah, Kingsley, Atia, Jolene, Atkin, Catherine, Aujayeb, Avinash, Awad, Elsayed M, Azab, Mohammed A, Azam, Mohammad T, Aziz, Sally, Azzam, Ahmed Y, Babar, Laxmi, Babb, Laura, Badh, Manpreet, Baguneid, Clare, Bailey, Emily, Baili, Efstratia, Baldwin, Sarah, Baloyiannis, Ioannis, Bannerjee, Moulinath, Barnard, Anna, Barra, Fabio, Bashir, Hannah, Bawor, Monica, Bayhan, Zülfü, Belcher, James, Belgamwar, Ravindra, Bentley, Corrina, Birchenough, Amy, Bo, Yen Nee J, Boden, Hayley R, Bouhuwaish, Ahmad, Brachini, Gioia, Bremner, Laura, Bridgwater, Hannah, Bryant, Catherine, Budd, Gabrielle, Budd, Sharon, Budzikoski, Adam, Bulla, Reem, Buondonno, Antonio, Burden, Nicole, Butt, Hejab, Capoglu, Recayi, Caracostea, Andra, Cardoso, Rifa, Carr, Alexis, Carrasco-Prats, Milagros, Cattel, Caterina, Ceccarelli, Giancarlo, Cecere, Giuseppe, Charalabopoulos, Alexandros, Charsley, Evelyn, Cheney-Lowe, Hannah, Chevallier, Theodore, Choudhry, Asad J, Ciccarone, Flavia, Cicerchia, Pierfranco M, Cirillo, Bruno, Collins, Fatma D, Comerford, Victoria, Cordie, Ahmed, Coulter, Siobhan, Coulthard, Nick, Cox, Catrin, Cox, Victoria, Crowe, Andrew, Cullen, Jack, Cummings, Jean, Cunningham, Niamh, Curley, Daniel, Currie, Hannah, Daly, Madeleine, Darley, Jay, Dattani, Nikhita, Davakis, Spyridon, Davies, Rowan, De Paola, Gilda, De Toma, Giorgio, Del Valle-Ruiz, Sergio, Deldar, Benyamin, Demir, Hakan, Desai, Arjun, Desai, Nirali, Devaney, Alice, Dew, Lindsey, Dhesi, Jugdeep, Dias, Maria, Dick, Gordon, Doddamani, Parveen, Dogra, Gurinder, Doll, Tina, Dooley, Hannah C, Dost, Samiullah, Dotchin, Catherine, Dowell, Hannah, Draghita, Ioan M, Dundas, James M, Duranti, Giulia, Dusara, Hiren, Dwivedi, Rajesh, Dyer, Adam H, Eastaugh, Alison, Edwards, Elinor, Elghazaly, Shrouk M, Elmehrath, Ahmed O, Elrick, Hope, El-Shazly, Mostafa, Emery, Alexander, Etchill, Eric W, Evans, Sarah, Evison, Felicity, Fairhead, Cassandra, Faulkner, Margherita, Felska, Agnieszka, Fernandez, Antia, Fernández-Fernández, Pedro V, Ferraiolo, Antonella, Ferrero, Simone, Fiori, Enrico, Firat, Necattin, Fisk, Gracie, Fleck, Anna, Fonsi, Giovanni B, Gabre-Kidan, Alodia, Gallo, Gaetano, Gandhi, Ratnam, Garner, Madeleine, Georgiou, Nikolaos, Gerretsen, Hannah, Ghannam, Nourhan A A, Ghobrial, Andrew, Ghobrial, Hedra, Ghufoor, Zaynub, Gibbon, Jake, Gilbert, Georgia F, Giles, Marie, Giménez-Francés, Clara, Gonullu, Emre, Gray, Amy, Gray, Joshua H, Green, Deirdre, Greene, Charlotte, Griffin, Ellanna, Griffith, Karla, Grubb, Anthony, Guan, Yue, Guerero, Daniel N, Gupta, Ayushi, Gustavino, Claudio, Guzman, Laurenny, Hadreiez, Ahmed K M, Hajiioannou, Jiannis, Hanji, Deevia, Madhavan, Deepthy Hari, Harmantepe, Tarık, Harrison, Patrick, Hart, Barbara, Haslam, Aidan, Haunton, Victoria, Haut, Elliott R, Heinsohn, Torben, Hennah, Lindsay, Hetta, Helal F, Hickman, Alexander, Hobill, Abigail, Hogan, Patrick C P, Hogan, Vesna, Holmes, Elizabeth, Honney, Katie, Hood, Katharine, Hopkinson, Katherine, Howells, Lara, Hrouda, Nicole, Hunsley, Danielle, Hurst, William, Hussein, Rand A, Ibrahim, Mohamed Eltaher A A, Ibtida, Ishmam, Ibukunoluwakitan, Aina, Ishlek, Irem, Iyer, Rishi, Jackson, Karl, Jackson, Rosie, James, Ellen, Jarvis, Hayley, Jeffs, Sophie, Jenko, Nathan, Jeyakumar, Sasha, Kabir, Shahriar, Kainth, Harjinder, Kalloo, Jason, Kanzaria, Akhil, Karapanou, Amalia, Kardaman, Nuha, Karthikeyan, Sandeep, Karunatilleke, Anne, Kelly, Mairead, Kelly, Nicola I, Khalid, Hesham, Khan, Haris, Khan, Muhammad S, King, Matthew, Kneen, Thomas, Kok, Li, Kratochwila, Chiara, Kuzeva, Aneliya, Lapolla, Pierfrancesco, Lau, Rebecca, Law, Kar Yee, Leadbetter, Aimee, Lee, Gabriel, Lee, Helena, Levinson, Gavriella, Lewis, Grace, Liakakos, Theodore, Lim, Stephen, Lis, Danielle, Livesey, Emma, López-Morales, Pedro, Lowes, Lily, Lunt, Eleanor, Lyon, Emily, Madan, Suvira, Majid, Zeinab, Malapati, Harsha, Man, Jade, Mandane, Baguiasri, Manning, Sarah H, Mantoglu, Baris, Martínez-Sanz, Nuria, Marx, William, Masood, Almontacer E B, Maughan, Tom, Mawhinney, Jamie, Maxfield, Dominic, Mayer, Jordan, Maynard, Henry, McDonald, Claire, McGovern, Aine, Mclachlan, Sophie, Medina-Manuel, Esther, Meneghini, Simona, Metcalf, Michelle, Millwood-Hargrave, John, Mingoli, Andrea, Miu, Kelvin, Mohamed, Fawsiya, Mohamed, Soha M, Hussein, Aliae A R Mohamed, Mohammad, Abdulkader, Mohammed, Aaliya, Momen, Ahmed A, Moomo, Farhana, Mora-Guzmán, Ismael, Moriarty, Lizzie, Morrin, Hamilton, Morris, Claire, Moss, Nicholas, Moustafa, Mohamed M, Mpoura, Maria, Mubin, Mohammed, Muhtaroglu, Ali, Muir, Georgina, Mulhern, Stephanie, Muller, Daniel, Murphy, Declan C, Muzammil, Bushra, Nadkarni, Varun, Nageh, Mariam Albatoul, NasrEldin, Yasmin K, Nawaz, Wasim, Nguyen, Hanna, Cheallaigh, Cliona Ni, Noar, Alexander, North, Samuel, Nwolu, Favour, O’Docherty, Alice, Odutola, Omoteniola, O’Dwyer, Sinead, Ogochukwu, Olebu, O’Mahony, Catherine, Orlando, Lia, Osterdahl, Marc, Page, Christina, Panayotidis, Ismini, Pancholi, Shivam, Parkin, Jessica, Passby, Lauren C, Pastor-Pérez, Patricia, Patel, Harnish, Patel, Shefali, Penfold, Rose, Perinpanathan, Rupini, Perivoliotis, Konstantinos, Perra, Teresa, Pinkney, Martha, Pinotti, Enrico, Porcu, Alberto, Price, Angeline, Pugliese, Francesco, Puri, Prabhleen, Pytraczyk, Sylvia, Qaiser, Yusra, Qurashi, Maria, Radenkovic, Dina, Rajeswaran, Thurkka, Rapaport, Sarah F, Razzak, Tahmina, Reilly, Lara, Reynolds, Paul, Richardson, Alexandra, Roberts, Amelia, Roberts-Rhodes, Charlotte, Robinson, Tanya, Rocca, Aldo, Ross-Skinner, Emily, Ruiz-Marín, Miguel, Ryall, Rebecca, Saad, Alshaimaa M, Saad, Mahmoud M, Sadiq, Ambreen, Sammarco, Giuseppe, Sampanis, Michail A, Sanghvi, Hazel, Sapienza, Paolo, Sayers, Ross, Scott, Luca, Sen, Michael, Shaban, Mosab A A, Shakespeare, Kathleen T, Shaw, Ellie, Shaw, Hannah, Sheldrake, Jonathan, Sim, Sing Yang, Simonelli, Luigi, Sipsas, Nikolaos V, Sivam, Jarita, Sivarajan, Sri, Smith, Jennifer, Speranza, Fabio, Spice, Claire, Stafford, Amanda, Stambollouian, Katharine, Stevens, Kent A, Stewart, Jack, Stratton, Emma, Street, Hannah, Surtees, Michael, Swinnerton, Emma, Taher, Ahmed S A, Tait, Caroline, Taylor, Amybel, Thake, Miriam, Thin, Katie, Thould, Hannah, Thyn, Thyn, To, Benjaman, Tobiss, Hannah, Toppley, Kathryn, Townsend, Liam, Tullo, Ellen, Tzovaras, George, Umeadi, Anthony, Vaidya, Hrisheekesh, Valero-Soriano, María, Varden, Rosanna, Vergani, Vittoria, Vervoort, Dominique, Vescio, Giuseppina, Vettasseri, Mark, Virk, Madiha, Vyas, Vaishali, Wagland, Joanne, Wallis, Stephanie, Warner, Chloe, Watkins, Eleanor, Watson, Hannah, Webb, Rachael, Welsh, Sarah H, West, Ruth, Whelan, Elisha, Whitney, Julie, Whitsey, Mark, Wilcock, Catherine, Wilkinson, Iain, Williams, David, Williamson, Megan, Willott, Ruth H, Wimalasundera, Mettha, Win, Yu Lelt, Winter, Laura, Worrall, Stephanie, Wright, Rebecca, Yeo, Natalie, Yeung, Eirene, Yigit, Merve, Yildiz, Yasin A, Yusuf, Humza, Zambon, Martina, Zaw, Hein, and Elabedeen, Omar Zein

Subjects
Male, Aging, medicine.medical_specialty, Frail Elderly, COVID-19, delirium, frailty, mortality, transitions of care, Cohort Studies, AcademicSubjects/MED00280, Interquartile range, Internal medicine, medicine, Dementia, Humans, Survivors, Aged, Proportional hazards model, business.industry, SARS-CoV-2, Hazard ratio, Odds ratio, General Medicine, medicine.disease, Confidence interval, frailty,COVID-19, Ageing, Delirium, Female, medicine.symptom, Geriatrics and Gerontology, business, Cohort study, Research Paper
Abstract

Introduction Increased mortality has been demonstrated in older adults with coronavirus disease 2019 (COVID-19), but the effect of frailty has been unclear. Methods This multi-centre cohort study involved patients aged 18 years and older hospitalised with COVID-19, using routinely collected data. We used Cox regression analysis to assess the impact of age, frailty and delirium on the risk of inpatient mortality, adjusting for sex, illness severity, inflammation and co-morbidities. We used ordinal logistic regression analysis to assess the impact of age, Clinical Frailty Scale (CFS) and delirium on risk of increased care requirements on discharge, adjusting for the same variables. Results Data from 5,711 patients from 55 hospitals in 12 countries were included (median age 74, interquartile range [IQR] 54–83; 55.2% male). The risk of death increased independently with increasing age (>80 versus 18–49: hazard ratio [HR] 3.57, confidence interval [CI] 2.54–5.02), frailty (CFS 8 versus 1–3: HR 3.03, CI 2.29–4.00) inflammation, renal disease, cardiovascular disease and cancer, but not delirium. Age, frailty (CFS 7 versus 1–3: odds ratio 7.00, CI 5.27–9.32), delirium, dementia and mental health diagnoses were all associated with increased risk of higher care needs on discharge. The likelihood of adverse outcomes increased across all grades of CFS from 4 to 9. Conclusion Age and frailty are independently associated with adverse outcomes in COVID-19. Risk of increased care needs was also increased in survivors of COVID-19 with frailty or older age.

Published
2021

30. RETRACTED ARTICLE: Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study

Author

El-Bendary, Mahmoud, primary, Abd-Elsalam, Sherief, additional, Elbaz, Tamer, additional, El-Akel, Wafaa, additional, Cordie, Ahmed, additional, Elhadidy, Tamer, additional, Elalfy, Hatem, additional, Farid, Khaled, additional, Elegezy, Mohamed, additional, El-Badrawy, Adel, additional, Neamatallah, Mustafa, additional, Abd Elghafar, Mohamed, additional, Salama, Marwa, additional, AbdAllah, Mohamed, additional, Essam, Mahmoud, additional, El-Shazly, Mostafa, additional, and Esmat, Gamal, additional

Published
2021
Full Text
View/download PDF

31. Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation

Author

Sabry, Nirmeen, Kamel, Ahmed M., Cordie, Ahmed, and Esmat, Gamal

Abstract

ABSTRACTIntroductionGlobally, it is estimated that 290,000 patients infected with hepatitis C virus (HCV) died from hepatitis C consequences, including cirrhosis and hepatocellular carcinoma in 2019. Although daclatasvir (DCV), combined with sofosbuvir (SOF), is effective in HCV patients, the new pan-genotypic combinations are considered by many as more cost-effective and successful in eradicating HCV infection.Areas coveredThis review discusses the safety, efficacy, and cost-effectiveness of DCV as an HCV treatment option based on real-world studies and pharmacoeconomic evaluations.Expert opinionReal-life studies suggest that SOF/DCV has acceptable sustained virological response and can be used successfully to manage HCV. Nonetheless, the use of SOF/DCV is limited by the longer treatment duration in genotype (GT)-3 patients and the need for ribavirin (RBV) in treatment-experienced patients which increases the likelihood of adverse effects. DCV is likely to remain as a therapeutic option for the management of GT-1, GT-2, and GT-4 patients in resource limited settings, while GT-3 patients are more likely to benefit from RBV-free direct-acting antiviral combinations such as SOF/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 weeks. The introduction of generics for these new pan-genotypic drugs would likely eliminate the need for SOF/DCV in the near future.

Published
2023
Full Text
View/download PDF

33. Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study

Author

Abd‐Elsalam, Sherief, primary, Noor, Rasha A., additional, Badawi, Rehab, additional, Khalaf, Mai, additional, Esmail, Eslam S., additional, Soliman, Shaimaa, additional, Abd El Ghafar, Mohamed S., additional, Elbahnasawy, Mohamed, additional, Moustafa, Ehab F., additional, Hassany, Sahar M., additional, Medhat, Mohammed A., additional, Ramadan, Haidi Karam‐Allah, additional, Eldeen, Maii A. S., additional, Alboraie, Mohamed, additional, Cordie, Ahmed, additional, and Esmat, Gamal, additional

Published
2021
Full Text
View/download PDF

35. Current status of hepatitis C virus among people living with human immunodeficiency virus in Egypt.

Author

Elsharkawy, Aisha, Alem, Shereen Abdel, Cordie, Ahmed, Mohamed, Rahma, Meshaal, Safa, and Esmat, Gamal

Subjects
HIV, HEPATITIS C virus, HIV infections, VIRAL load, ENZYME-linked immunosorbent assay
Abstract

Background Human immunodeficiency virus (HIV)–hepatitis C virus (HCV) co-infection is increasing due to their similar routes of transmission. Co-infection poses a big challenge. Information on the prevalence of HCV infection in Egyptian HIV individuals is scarce. Methods A cross-sectional study was conducted on 1004 HIV individuals who were recruited from July 2018 to March 2019. Blood samples obtained from HIV individuals were subsequently screened for HCV antibodies using the Murex anti-HCV (version 4) enzyme-linked immunosorbent assay test. HCV RNA was performed only on anti-HCV antibody–positive samples. Logistic regression was used to identify factors associated with HCV seroprevalence using SPSS (IBM, Armonk, NY, USA). Results Among 1004 participants, 349 exhibited a positive result for anti-HCV antibodies (34.8% [95% confidence interval 31.81 to 37.8]). The most commonly self-reported risk factor of HIV infection by the co-infected participants was intravenous drug use (IDU) (303/349 [86.8%]). In multinomial analysis, risk factors identified as statistically associated with HCV seroprevalence include IDU, history of surgical operations and dental procedures and HIV viral load (p<0.001, 0.032, <0.001 and 0.006, respectively). Under combination antiretroviral therapy (cART), the proportion of HIV mono-infected individuals with an undetectable HIV viral load was significantly higher than those with co-infection (p<0.0007). We also found that HIV–HCV co-infected participants exhibited significantly higher CD4+ cell counts than those with HIV mono-infection (p=0.04). Conclusions The prevalence of HIV–HCV co-infection is higher in Egypt compared with other countries in Africa. It is essential to screen all HIV-infected patients for HCV infection for early identification, counselling and initiation of anti-HCV treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. evolving challenges confronting adults living with HIV in three North African countries during the COVID-19 crisis: a survey-based study.

Author

Cordie, Ahmed, AbdAllah, Mohamed, Desouky, Eman El, Kheir, Sara Gabrallah Mohamed, Kooli, Ikbal, Mousnad, Mohamed Awad, Idris, Fatima Haj, Abdella, Heba, Chakroun, Mohamed, and Esmat, Gamal

Subjects
COVID-19 pandemic, COVID-19, INFLUENZA, HIV protease inhibitors, HIV, COUGH, HIV-positive persons
Abstract

Background Coronavirus disease 2019 (COVID-19) has resulted in a huge burden on healthcare systems, especially on programs for chronic illnesses such as HIV. We aimed to assess the challenges confronting adult people living with HIV (PLHIV) in three countries in North Africa during the COVID-19 crisis and their awareness of COVID-19 non-pharmaceutical preventive measures. Methods This online survey included PLHIV aged ≥18 y from three countries in North Africa recruited by a snowball sampling technique, who were asked to complete a modified questionnaire originally developed by the University of Antwerp in Belgium, which was then disseminated through social media tools to assess the study outcomes. Results Out of 369 respondents, 260 (70.5%) were males and 237 (64.2%) were aged 18–39 y. Adherence to COVID-19 preventive measures, wearing facemasks (308 [83.2%]), applying hand-sanitizers (299 [80.8%]) and following cough etiquette (261 [70.5%]), were predominantly reported. Only 48 (13%) were vaccinated against influenza. One hundred and forty-five participants (42%) experienced flu-like symptoms, 29 (20%) were tested for COVID-19, with only one confirmed case identified. Among 344 (93.2%) on antiretroviral therapy (73.8% efavirenz- vs 6.4% dolutegravir-based regimens), 219 (63.7%) attended their scheduled visits, 144 (41.9%) had limited access to care due to lockdown and 29 (8.4%) became less adherent to their antiretroviral therapy. Covariates associated with challenges during access to care were age ≥60 y (OR=6.5; 95% CI 1.8 to 23.2) and receiving second-line HIV treatment such as protease inhibitors (OR=2.7; 95% CI 1.3 to 5.8). Conclusion The pandemic adversely affected PLHIV. New innovative strategies should be implemented to ensure the continuity of HIV services. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

37. Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience.

Author

Abdelaziz, Hossam, Omar, Heba, Khalil, Mahmoud, Cordie, Ahmed, Mohamed, Rahma, AbdAllah, Mohamed, Abdel Maksoud, Mohammed Hamdy, El Garhy, Naeema, Ali, Lamiaa, El Serafy, Magdy, Esmat, Gamal, and Doss, Wahid

Abstract

Liver disease has emerged as a leading cause of death among PLHIV coinfected with HCV. A retrospective study involving all HCV viremic patients coinfected with HIV who presented to HCV/HIV multidisciplinary clinics located at Embaba fever hospital. Patients were assigned to receive DAAs according to the national treatment guidelines. The primary endpoint was SVR12. Of the 519 patients enrolled, 38.73% LTFU; either not initiated (n = 170) or did not complete the treatment (n = 31). The main identified reasons behind LTFU were schedule conflict (19%) or hospitalization (13%). Among 318 patients who completed their DAAs course, nine patients had a relapse after the end of treatment and 97% had attained SVR12. There were significant differences among different virological response groups in baseline factors including smoking (p = 0.005), history of dental procedure (p = 0.007), CD4 count (p = 0.007), and HIV viral load (p = <0.001). Among responders (n = 309), there was a significant reduction of baseline hemoglobin and significant improvement of baseline platelets (p = 0.005) at on-treatment week 8. Baseline necro-inflammatory markers showed significant improvement across follow-up time points (p < 0.001). DAAs are an effective and safe choice to treat HCV in PLHIV. Social stigma could be a major cause for lacking adherence to follow-up visits. Abbreviations: ALT: Alanine Aminotransferase; ARV: Antiretroviral treatment; AST: Aspartate Aminotransferase; DAAs: Direct acting antivirals; ARVs: antiretroviral therapy; EMR: Eastern Mediterranean region; HCV: Hepatitis C virus; kPa: Kilopascal; LTFU: Patient lost to follow up; NCCVH: The National Committee for Control of Viral Hepatitis; PWID: People who inject drugs; SVR: Sustained virological response;UNAIDS: The Joint United Nations Programme on HIV/AIDS [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Screening and Treatment Program to Eliminate Hepatitis C in Egypt

Author

Waked, Imam, primary, Esmat, Gamal, additional, Elsharkawy, Aisha, additional, El-Serafy, Magdy, additional, Abdel-Razek, Wael, additional, Ghalab, Reham, additional, Elshishiney, Galal, additional, Salah, Aysam, additional, Abdel Megid, Soad, additional, Kabil, Khaled, additional, El-Sayed, Manal H., additional, Dabbous, Hany, additional, El Shazly, Yehia, additional, Abo Sliman, Mohamed, additional, Abou Hashem, Khalid, additional, Abdel Gawad, Sayed, additional, El Nahas, Nevine, additional, El Sobky, Ahmed, additional, El Sonbaty, Sahar, additional, El Tabakh, Hamdy, additional, Emad, Ehab, additional, Gemeah, Hany, additional, Hashem, Amal, additional, Hassany, Mohamed, additional, Hefnawy, Naseif, additional, Hemida, Abdel N., additional, Khadary, Ayman, additional, Labib, Kamal, additional, Mahmoud, Faisal, additional, Mamoun, Said, additional, Marei, Tamer, additional, Mekky, Saad, additional, Meshref, Alsayeda, additional, Othman, Alaa, additional, Ragab, Omnia, additional, Ramadan, Elhag, additional, Rehan, Ahmed, additional, Saad, Tarek, additional, Saeed, Ramy, additional, Sharshar, Mohamed, additional, Shawky, Hesham, additional, Shawky, Mohamed, additional, Shehata, Wael, additional, Soror, Hanaa, additional, Taha, Mohsen, additional, Talha, Mahmoud, additional, Tealaab, Adel, additional, Zein, Mohamed, additional, Hashish, Alaa, additional, Cordie, Ahmed, additional, Omar, Yasser, additional, Kamal, Ehab, additional, Ammar, Islam, additional, AbdAlla, Mohamed, additional, El Akel, Wafaa, additional, Doss, Wahid, additional, and Zaid, Hala, additional

Published
2020
Full Text
View/download PDF

43. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection

Author

Cordie, Ahmed, primary, Elsharkawy, Aisha, primary, Abdel Alem, Shereen, primary, Meshaal, Safa, primary, El Akel, Wafaa, primary, Abdellatif, Zeinab, primary, Kamal, Walid, primary, Al Askalany, Mahmoud, primary, Kamel, Sherif, primary, Abdel Aziz, Hossam, primary, Kandeel, Amr, primary, and Esmat, Gamal, primary

Published
2020
Full Text
View/download PDF

44. Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma

Author

Abdelaziz, Ashraf Omar, Abdelmaksoud, Ahmed Hosni, Nabeel, Mohamed Mahmoud, Shousha, Hend Ibrahim, Cordie, Ahmed Abdelmonem, Mahmoud, Sherif Hamdy, Medhat, Eman, Omran, Dalia, and Elbaz, Tamer Mahmoud

Subjects
Hepatocellular carcinoma, microwave ablation, radiofrequency ablation, Research Article
Abstract

Introduction: Local ablative therapy and trans arterial chemoembolization (TACE) are applied to ablate non resectable hepatocellular carcinoma (HCC). Combination of both techniques has proven to be more effective. We aimed to study combined ablation techniques and assess survival benefit comparing TACE with radiofrequency (RFA) versus TACE with microwave (MWA) techniques. Methods: We retrospectively studied 22 patients who were ablated using TACE-RFA and 45 with TACE-MWA. All were classified as Child A-B and lesions did not exceed 5 cm in diameter. TACE was followed within two weeks by either RFA or MWA. We recorded total and partial ablation rates and complication rates. Survival analysis was then performed. Results: TACE-MWA showed a higher tendency to provide complete response rates than TACE-RFA (P 0.06). This was particularly evident with lesions sized 3-5 cm (P 0.01). Rates of complications showed no significant difference between the groups. Overall median survival was 27 months. The overall actuarial probability of survival was 80.1% at 1 year, 55% at 2 years, and 36.3% at 3 years. The recurrence free survival at 1 year, 2years and 3 years for the TACE-RFA group was 70%, 42% and 14% respectively and for TACE-MWA group 81.2%, 65.1% and 65.1% without any significant difference (P 0.1). In relation to the size of focal lesions, no statistically significant difference in the survival rates was detected between the groups. Conclusion: TACE-MWA led to better response rates than TACE-RFA with tumors 3-5 cm, with no difference in survival rates.

Published
2017

45. HCV/HIV coinfected Egyptian patients: a cross-sectional study of their main characteristics and barriers to HCV treatment initiation.

Author

Eletreby, Rasha, Esmat, Gamal, Elsharkawy, Aisha, Alsehemy, Lamiaa, Mohamed, Rahma, Alem, Shereen Abdel, Yousof, Hanaa, Cordie, Ahmed, and Lithy, Rania M

Subjects
MIXED infections, MEDICAL personnel, HIV, HEALTH facilities, PATIENT compliance
Abstract

Background This study investigates different barriers preventing a cohort of Egyptian HIV/HCV coinfected patients from accessing HCV treatment, despite being available and free of charge, aiming to improve the long-term outcomes of coinfected patients and decreasing their liver-related morbidity and mortality. Methods This study included HIV patients who were referred to Kasr Alainy Viral Hepatitis Center to receive HCV treatment and who had to continue pretreatment assessment in order to receive direct acting antiviral agents free of charge. Patients who did not attend within 90 d were questioned via a telephone interview. Questions addressed sociodemographic status, HIV status and the main barriers to accessing healthcare. Results Overall, 474 HIV/HCV coinfected patients were eligible for HCV treatment and 223 (47.1%) patients did not complete work-up for HCV treatment. Fear of community stigma concerning HIV/HCV was the most important barrier to compliance with treatment (73.3%), followed by lack of a supportive work environment and employment opportunities (51.5%), whereas 39.3% stopped follow-up due to the lack of integrated services in the healthcare facility. Conclusions Managing HCV in HCV/HIV coinfected patients still represents a major challenge, not only for healthcare providers, but also at a community level, to improve community awareness and manage the major obstacle facing those patients regarding community stigma. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.

Author

El-Bendary, Mahmoud, Abd-Elsalam, Sherief, Elbaz, Tamer, El-Akel, Wafaa, Cordie, Ahmed, Elhadidy, Tamer, Elalfy, Hatem, Farid, Khaled, Elegezy, Mohamed, El-Badrawy, Adel, Neamatallah, Mustafa, Abd Elghafar, Mohamed, Salama, Marwa, AbdAllah, Mohamed, Essam, Mahmoud, El-Shazly, Mostafa, and Esmat, Gamal

Abstract

Limited experimental and clinical evidence suggests a potential role for sofosbuvir/daclatasvir in treating COVID19. We aim to evaluate the efficacy of generic sofosbuvir/daclatasvir in treating COVID-19 patients with pneumonia. This multicenter prospective study involved 174 patients with COVID-19. Patients were randomized into two groups. Group A (96 patients) received sofosbuvir (400 mg)/daclatasvir (60 mg) for 14 days in combination with conventional therapy. Group B (78 patients) received conventional therapy alone. Clinical, laboratory, and radiological data were collected at baseline, after 7, 14, and 28 days of therapy. Primary endpoint was rate of clinical/virological cure. A lower mortality rate was observed in group (A) (14% vs 21%, P = 0.07). After 1 month of therapy, no differences were found in rates of ICU admission, oxygen therapy, or ventilation. Additionally, a statistically significant shorter duration of hospital stay (9% vs 12%, P < 0.01) and a faster achievement of PCR negativity at day 14 (84% versus 47%, P < 0.01) were noticed in group (A). Adding sofosbuvir/daclatasvir to conventional therapy of COVID-19 is promising. Their use is associated with shorter hospital stay, faster PCR negativity and may be reduced mortality. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Reactogenicity of COVID-19 Vaccines; Insights from Cairo University Hospitals.

Author

Sayed, Amal M., Ahmed, Marwa M., Fares, Samar, Cordie, Ahmed, Elkashef, Sabrin M. M., Ezzelarab, Moushira Hosny, and Talaate, Hala Salah Eldin

Subjects
*MEDICAL personnel, *COVID-19 vaccines, *UNIVERSITY hospitals, *COVID-19 pandemic, *VACCINE development
Abstract

Background: Since the emergence of the COVID-19 pandemic, most of the efforts were directed towards developing new vaccines that are safe and effective to terminate the pandemic. Methods: This is a cross-sectional study, to analyze the short-term side effect profile of the AstraZeneca/Oxford vaccine and Sinopharm Chinese vaccine. A quantitative survey using Google Forms was used for healthcare workers at Cairo University Hospitals from February to May 2021. From total of 4962 healthcare workers who received COVID-19 vaccines through this period, 1190 responded to the questionnaire. The collected data included side effects, duration, and symptoms' severity. Results: Around 50% and 20% of the participants did not report any symptoms after Sinopharm and AstraZeneca vaccines, respectively. Participants receiving AstraZeneca vaccine were 3.6 times more likely to have fever compared to those receiving Sinopharm [OR (95%CI) 3.62 (2.18-6.04)]. Also, they were more likely to have mild, moderate, and severe local reaction in comparison with those receiving Sinopharm [OR (95%CI) 2.01 (1.46-2.78), 6.13 (3.29-11.40), and 6.06 (1.07-34.33), respectively]. The duration of symptoms of both vaccines did not differ. Conclusion: While both vaccines were safe, the healthcare workers who received Sinopharm vaccine showed significantly fewer side effects compared to AstraZeneca recipients. [ABSTRACT FROM AUTHOR]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results